Preclinical evidence consistently demonstrates that incretin-based anti-obesity medications such as GLP-1 RAs may have direct positive effects on skeletal muscle beyond their roles in glucose regulation and weight loss. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.